Search

Your search keyword '"Rodriguez-Macias, Gabriela"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Rodriguez-Macias, Gabriela" Remove constraint Author: "Rodriguez-Macias, Gabriela"
31 results on '"Rodriguez-Macias, Gabriela"'

Search Results

1. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

4. Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

5. Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine

7. Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.

9. Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

10. Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

11. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

12. Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

15. Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification

16. Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

17. Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

19. An ex vivo native environment precision medicine AML test and the correlation with responses to 1st line treatment.

20. A Prognostic Index for Patients with Refractory or in First Relapsed Acute Myeloid Leukemia Treated with FLAG-Ida or Flago-Ida

23. High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

24. Natural Killer (NK) Cell Reconstitution After Haploidentical Unmanipulated Bone Marrow Transplantation with Reduced Intensity Conditioning

26. Bcl2 Over-Expression as a Prognostic factor In Hodgkin Lymphoma Patients who Required Intensive Treatment

28. Allogeneic Hematopoietic Stem Cell Transplantation in HIV-Positive Patients with High Risk Hematologic Malignancies

29. The ANALYSIS of Chimerism IN ACTIVATED T Lymphocites CD25+ Improves the CAPACITY of the T Lymphocytes CD3+ Chimerism Dinamic to Predict COMPLICATIONS AFTER Allogenic STEM CELL TRANSPLANTATION

30. Efficient Identification of Response to Cytarabine Idarubicin in Newly Diagnosed Acute Myeloid Leukemia by a New Individualized Medicine Test Based on ex vivo Pharmacology

31. 1st Line AML Equivalent Treatments Cytarabine Plus an Anthracyclin (Ida, Dau, Mit) Show Alternative Sensitive/Resistant Profiles in ex vivo Patient Sample Chemosensitivity; Could Personalizing be the Key Selection Criterion?

Catalog

Books, media, physical & digital resources